ストックスクリーナーアプリを入手
7.77
0.13%
0.010
アフターアワーズ：
7.77
前日終値:
$7.76
開ける：
$7.752
24時間の取引高:
619.60K
Relative Volume:
0.65
時価総額：
$401.03M
収益：
$170.44M
当期純損益:
$-193.88M
株価収益率:
-2.0697
EPS:
-3.7541
ネットキャッシュフロー:
$-126.38M
1週間 パフォーマンス:
-6.83%
1か月 パフォーマンス:
-14.05%
6か月 パフォーマンス:
-19.48%
1年 パフォーマンス:
-0.77%
1日の値動き範囲:
$7.58
$7.885
1週間の範囲:
$7.58
$8.78
52週間の値動き範囲:
$5.035
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Compare RGNX vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.77 | 400.52M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
443.16 | 110.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.29 | 77.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
704.31 | 42.91B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
316.09 | 42.09B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
153.32 | 31.32B | 606.42M | -1.28B | -997.58M | -6.403 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2025-02-11 | ダウングレード | Goldman | Buy → Neutral |
| 2025-02-07 | 再開されました | Raymond James | Outperform |
| 2024-11-15 | 再開されました | Morgan Stanley | Overweight |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-06-07 | 開始されました | Goldman | Buy |
| 2024-03-11 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-08 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 再開されました | Raymond James | Outperform |
| 2023-11-01 | 開始されました | Stifel | Buy |
| 2023-06-02 | 開始されました | Robert W. Baird | Outperform |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-15 | 開始されました | Wedbush | Neutral |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-01-06 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-06-25 | 再開されました | BofA/Merrill | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-06-14 | 再開されました | Raymond James | Outperform |
| 2019-06-05 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-02-25 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-02-05 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-11-08 | 繰り返されました | BofA/Merrill | Neutral |
| 2018-08-08 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-23 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-05-09 | 繰り返されました | Barclays | Overweight |
| 2018-04-09 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 開始されました | Mizuho | Neutral |
| 2017-11-09 | 再開されました | Morgan Stanley | Overweight |
すべてを表示
Regenxbio Inc (RGNX) 最新ニュース
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire Inc.
REGENXBIO Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 - PR Newswire
Gene Therapy And US Patent Eligibility Update: REGENXBIO, Inc. v. Sarepta Therapeutics, Inc. - marketscreener.com
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 earnings call transcript - MSN
RGNX Stockholders Have Opportunity to Lead REGENXBIO Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Vanguard (RGNX) disaggregates holdings; reports 0 shares after realignment - Stock Titan
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO ... - Bluefield Daily Telegraph
RGNX Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - marketscreener.com
REGENXBIO Inc. $RGNX Shares Purchased by Assenagon Asset Management S.A. - MarketBeat
ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ROSEN, NATIONAL TRIAL LAWYERS, Encourages REGENXBIO, Inc. - GlobeNewswire
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming DeadlinesRGNX - PR Newswire
RGNX SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - marketscreener.com
SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD - finviz.com
Momentum Shift: Can REGENXBIO Inc deliver consistent dividendsEarnings Overview Summary & Verified Swing Trading Watchlist - baoquankhu1.vn
Panic Selling: Is REGENXBIO Inc impacted by rising ratesQuarterly Trade Review & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm - Sahm
Stop Loss: Is REGENXBIO Inc impacted by rising ratesWeekly Trade Summary & Weekly High Return Opportunities - baoquankhu1.vn
Sarepta Urges Full Fed. Circ. To Wipe Out Gene Therapy IP - Law360
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP - pharmiweb.com
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - ChartMill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX - ChartMill
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - FinancialContent
Patient centric approach drives AFFINITY DUCHENNE study expansion at REGENXBIO - Traders Union
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Regenxbio says its gene therapy for muscle disorder showed no evidence of liver injury in study - MSN
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel ... - Caledonian Record
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: LEVI & KORSINSKY, LLP - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - GlobeNewswire
RGNX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com
RGNX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - Sahm
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
REGENXBIO Inc. $RGNX Shares Bought by JPMorgan Chase & Co. - MarketBeat
RGX-111 Security Concerns Approaching April 14 Cutoff: Legal Resolution or Trigger for Market Decline? - Bitget
REGENXBIO Inc. Files Form 8-K Announcing Material Definitive Agreement – Company Information and NASDAQ Listing Details - Minichart
Form 8K Regenxbio Inc For: 20 March By Investing.com - Investing.com Australia
Regenxbio reaches $10 million settlement with GlaxoSmithKline over sublicense fees - Investing.com
Form 8K Regenxbio Inc For: 20 March - Investing.com
According to the latest filing from the U.S. Securities and Exchange Commission (SEC), biotechnology company Regenxbio Inc has officially signed a settlement and release agreement with pharmaceutical giant GlaxoSmithKline. - Bitget
Regenxbio enters settlement and release agreement with GlaxoSmithKline on March 18, 2026SEC filing - marketscreener.com
According to a document submitted to the U.S. Securities and Exchange Commission, biotechnology company Regenxbio Inc has confirmed that it will continue, under its existing sublicensing agreement with pharmaceutical giant GlaxoSmithKline, to pay the l - Bitget
RegenXBio Reaches Settlement with GSK Over License Fees - TipRanks
Regenxbio Settles GSK Sublicense Fee Dispute With $10 Million Payment and Mutual Releases - TradingView
REGENXBIO (NASDAQ: RGNX) agrees $10M settlement payment to GSK - Stock Titan
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel ... - Bluefield Daily Telegraph
Regenxbio Inc (RGNX) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.04%
大文字化:
|
ボリューム (24 時間):